Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.52 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15111098 | 1.00 | MAP2K1 (0.52) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL21142972 | 1.00 | MAP2K1 (0.52) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL15537286 | 0.91 | MAP2K1 (0.53) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL5025825 | 0.91 | MAP2K1 (0.45) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL5023528 | 0.91 | MAP2K1 (0.54) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1527813 | 0.88 | MAP2K1 (0.42) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1527738 | 0.83 | MAP2K1 (0.45) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL28704528 | 0.83 | MAP2K1 (0.51) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL23037463 | 0.81 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL685422 | 0.80 | MAP2K1 (0.61) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4228624-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228639-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023154417-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4164653-A1 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | G1 Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023039208-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023034336-A2 | IMPROVED TREATMENTS FOR ADVANCED/METASTATIC CANCERS WITH CHECKPOINT INHIBITOR RESISTANCE OR RESISTANCE SUSCEPTIBILITY | G1 THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-2462111-A1 | PREPARATION OF (R)- AND (S)-N-(3, 4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)--6-METHOXYPHENYL) -1- (2, 3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND PROTECTED DERIVATIVES THEREOF | Ardea Biosciences, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| CN-102421427-A | Pharmaceutical combination comprising RDEA119/BAY869766 for the treatment of specific cancers | ARDEA BIOSCIENCES INC | 2012-04-18 | — | — | CN | disclosed |
| EP-2405908-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | Ardea Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2405908-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | Ardea Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011161216-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011009541-A1 | PREPARATION OF (R)- AND (S)-N-(3, 4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)--6-METHOXYPHENYL) -1- (2, 3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND PROTECTED DERIVATIVES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010105110-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105110-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING RDEA119/BAY 869766 FOR THE TREATMENT OF SPECIFIC CANCERS | ARDEA BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2184984-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | Ardea Biosciences, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009018233-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |